BioCentury
ARTICLE | Product Development

Rebuilding Biogen’s brain

What Biogen is building in neurology

May 5, 2018 1:46 AM UTC

Biogen Inc. is still a long way from a full rebuild of its pipeline, with an Alzheimer’s disease-laden Phase III lineup that needs to diversify. But there’s progress in the early- to mid-stage programs where the biotech has brought in new modalities and broadened its scope to encompass riskier targets for a growing range of neurology indications.

Its April 20 deal with Ionis Pharmaceuticals Inc. is the latest and biggest move Biogen has taken to bolster its long-term prospects for becoming the leader in neurology. ...